Literature DB >> 22426035

Effect of chronic sodium nitrite therapy on monocrotaline-induced pulmonary hypertension.

Edward A Pankey1, Adeleke M Badejo, David B Casey, George F Lasker, Russel A Riehl, Subramanyam N Murthy, Bobby D Nossaman, Philip J Kadowitz.   

Abstract

Pulmonary hypertension (PH) is a rare disorder that without treatment is progressive and often fatal within 3 years. The treatment of PH involves the use of a diverse group of drugs and lung transplantation. Although nitrite was once thought to be an inactive metabolite of endothelial-derived nitric oxide (NO), there is increasing evidence that nitrite may be useful in the treatment of PH, but the mechanism by which nitrite exerts its beneficial effect remains uncertain. The purpose of this study was to investigate the effect of chronic sodium nitrite treatment in a PH model in the rat. Following induction of PH with a single injection of monocrotaline, 60 mg; daily ip injections of sodium nitrite (3mg/kg) starting on day 14 and continuing for 21 days, resulted in a significantly lower pulmonary arterial pressure on day 35 when compared to values in untreated animals with monocrotaline-induced PH. In monocrotaline-treated rats, daily treatment with ip nitrite injections for 21 days decreased right ventricular mass and pathologic changes in small pulmonary arteries. Nitrite therapy did not change systemic arterial pressure or cardiac output when values were measured on day 35. The decreases in pulmonary arterial pressure in response to iv injections of sodium nitroprusside, sodium nitrite, and BAY 41-8543 were not different in rats with monocrotaline-induced pulmonary hypertension and rats with chronic nitrite therapy when compared to responses in animals in which pulmonary arterial pressure was increased with U46619. These findings are consistent with the hypothesis that the mechanisms that convert nitrite to vasoactive NO, activate soluble guanylyl cyclase and mediate the vasodilator response to NO or an NO derivative are not impaired. The present data are consistent with the results of a previous study in monocrotaline-induced PH in which systemic arterial pressure and cardiac output were not evaluated and are consistent with the hypothesis that nitrite is effective in the treatment of monocrotaline-induced PH in the rodent.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22426035      PMCID: PMC3366021          DOI: 10.1016/j.niox.2012.02.004

Source DB:  PubMed          Journal:  Nitric Oxide        ISSN: 1089-8603            Impact factor:   4.427


  78 in total

Review 1.  The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics.

Authors:  Jon O Lundberg; Eddie Weitzberg; Mark T Gladwin
Journal:  Nat Rev Drug Discov       Date:  2008-02       Impact factor: 84.694

2.  Plasma nitrite concentrations reflect the degree of endothelial dysfunction in humans.

Authors:  Petra Kleinbongard; André Dejam; Thomas Lauer; Thomas Jax; Stefan Kerber; Putrika Gharini; Jan Balzer; Rainer B Zotz; Rüdiger E Scharf; Reinhart Willers; Alan N Schechter; Martin Feelisch; Malte Kelm
Journal:  Free Radic Biol Med       Date:  2005-11-10       Impact factor: 7.376

3.  Xanthine oxidoreductase catalyses the reduction of nitrates and nitrite to nitric oxide under hypoxic conditions.

Authors:  T M Millar; C R Stevens; N Benjamin; R Eisenthal; R Harrison; D R Blake
Journal:  FEBS Lett       Date:  1998-05-08       Impact factor: 4.124

Review 4.  Nitric oxide: a unique endogenous signaling molecule in vascular biology.

Authors:  L J Ignarro
Journal:  Biosci Rep       Date:  1999-04       Impact factor: 3.840

5.  Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension.

Authors:  A Giaid; D Saleh
Journal:  N Engl J Med       Date:  1995-07-27       Impact factor: 91.245

6.  Mechanisms underlying erythrocyte and endothelial nitrite reduction to nitric oxide in hypoxia: role for xanthine oxidoreductase and endothelial nitric oxide synthase.

Authors:  Andrew J Webb; Alexandra B Milsom; Krishnaraj S Rathod; Wai Lum Chu; Shehla Qureshi; Matthew J Lovell; Florence M J Lecomte; David Perrett; Carmelo Raimondo; Espeed Khoshbin; Zubair Ahmed; Rakesh Uppal; Nigel Benjamin; Adrian J Hobbs; Amrita Ahluwalia
Journal:  Circ Res       Date:  2008-09-25       Impact factor: 17.367

Review 7.  Clinical translation of nitrite therapy for cardiovascular diseases.

Authors:  John W Calvert; David J Lefer
Journal:  Nitric Oxide       Date:  2009-11-10       Impact factor: 4.427

8.  A mammalian functional nitrate reductase that regulates nitrite and nitric oxide homeostasis.

Authors:  Emmelie A Jansson; Liyue Huang; Ronny Malkey; Mirco Govoni; Carina Nihlén; Annika Olsson; Margareta Stensdotter; Joel Petersson; Lena Holm; Eddie Weitzberg; Jon O Lundberg
Journal:  Nat Chem Biol       Date:  2008-05-30       Impact factor: 15.040

9.  Analysis of pulmonary vasodilator responses to SB-772077-B [4-(7-((3-amino-1-pyrrolidinyl)carbonyl)-1-ethyl-1H-imidazo(4,5-c)pyridin-2-yl)-1,2,5-oxadiazol-3-amine], a novel aminofurazan-based Rho kinase inhibitor.

Authors:  Jasdeep S Dhaliwal; Adeleke M Badejo; David B Casey; Subramanyam N Murthy; Philip J Kadowitz
Journal:  J Pharmacol Exp Ther       Date:  2009-04-15       Impact factor: 4.030

10.  Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical.

Authors:  L J Ignarro; R E Byrns; G M Buga; K S Wood
Journal:  Circ Res       Date:  1987-12       Impact factor: 17.367

View more
  12 in total

Review 1.  Inorganic nitrite supplementation for healthy arterial aging.

Authors:  Amy L Sindler; Allison E Devan; Bradley S Fleenor; Douglas R Seals
Journal:  J Appl Physiol (1985)       Date:  2014-01-09

Review 2.  Enterosalivary nitrate metabolism and the microbiome: Intersection of microbial metabolism, nitric oxide and diet in cardiac and pulmonary vascular health.

Authors:  Carl D Koch; Mark T Gladwin; Bruce A Freeman; Jon O Lundberg; Eddie Weitzberg; Alison Morris
Journal:  Free Radic Biol Med       Date:  2016-12-16       Impact factor: 7.376

3.  Recent publications by ochsner authors.

Authors: 
Journal:  Ochsner J       Date:  2012

Review 4.  New insights into the role of soluble guanylate cyclase in blood pressure regulation.

Authors:  Emmanuel Buys; Patrick Sips
Journal:  Curr Opin Nephrol Hypertens       Date:  2014-03       Impact factor: 2.894

Review 5.  A Brief Overview of Nitric Oxide and Reactive Oxygen Species Signaling in Hypoxia-Induced Pulmonary Hypertension.

Authors:  Ariel Jaitovich; David Jourd'heuil
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

Review 6.  Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

Authors:  A Dasgupta; L Bowman; C L D'Arsigny; S L Archer
Journal:  Clin Pharmacol Ther       Date:  2014-11-28       Impact factor: 6.875

7.  Intratracheal administration of cyclooxygenase-1-transduced adipose tissue-derived stem cells ameliorates monocrotaline-induced pulmonary hypertension in rats.

Authors:  Naveen K Somanna; Philipp M Wörner; Subramanyam N Murthy; Edward A Pankey; Deborah J Schächtele; Rose-Claire St Hilaire; David Jansen; Abigail E Chaffin; Bobby D Nossaman; Eckhard U Alt; Philip J Kadowitz; Reza Izadpanah
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-08-22       Impact factor: 4.733

8.  Analysis of responses to the TRPV4 agonist GSK1016790A in the pulmonary vascular bed of the intact-chest rat.

Authors:  Edward A Pankey; Andrea Zsombok; George F Lasker; Philip J Kadowitz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-11-01       Impact factor: 4.733

9.  Nitrate-nitrite-nitric oxide pathway in pulmonary arterial hypertension therapeutics.

Authors:  Courtney E Sparacino-Watkins; Yen-Chun Lai; Mark T Gladwin
Journal:  Circulation       Date:  2012-05-09       Impact factor: 29.690

10.  Oxidative Stress and Therapeutic Development in Lung Diseases.

Authors:  Leah Villegas; Timothy Stidham; Eva Nozik-Grayck
Journal:  J Pulm Respir Med       Date:  2014-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.